Noven Pharmaceuticals has acquired commercial rights to Minivelle (estradiol transdermal system) in the U.S. and Canada from Novogyne Pharmaceuticals, a women’s health joint venture between Noven and Novartis. Financial terms were not disclosed.
 
Noven will market and sell Minivelle through the Women’s Health unit of its subsidiary, Noven Therapeutics, LLC. Noven developed the Minivelle patch using its DOT Matrix transdermal delivery technology, and the product will be manufactured at its Miami, FL facility.
 
Minivelle is approved by the FDA for the treatment of moderate to severe vasomotor symptoms due to menopause. Noven expects that Minivelle will be available in the U.S. in 1Q13.